Oxular is proud to announce it has begun dosing in its OXEYE for diabetic macular edema (DME), a common retinal disorder with high treatment burden. In OXEYE, we are delivering Oxular’s suprachoroidal OXU-001, our sustained release microsphere formulation of dexamethasone, via Oxulumis®, our posterior suprachoroidal microcatheter delivery device, with an aim to provide a safe and …
For front page news
As we transition to mid-stage development with our #ophthalmic pipeline and platform, and look to optimize the application of our technologies, Mark Gaffney’s decades of experience in corporate and financing strategy, business development and operations will be invaluable to Oxular’s future growth Oxular Announces Appointment of Mark Gaffney as Chief Executive Officer | Business Wire
Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema OXU-001 represents potential best-in-class treatment for DME with just one, targeted administration per year Initiation of OXEYE Phase 2 clinical trial of OXU-001 in DME patients on-track for first quarter of 2023; Initial clinical data on safety and durability …
Oxular is thrilled to sponsor ISU 2022 in Utrecht, The Netherlands, and introduce the Oxulumis® suprachoroidal microcatheter to leading uveitis specialists. Together with Marc D. de Smet, we will host a series of skill transfer labs and provide hands-on instruction for routine suprachoroidal drug administration using Oxulumis®. We look forward to seeing you all there.
Our CEO, Tom Cavanagh, presented an overview of Oxular’s retinal therapeutics platform at Eyecelerator, during AAO 2021. It was a pleasure to share this update, with a specific focus on OXU-001, Oxular’s lead program investigating a long-lasting, suprachoroidally administered treatment for DME. You can read Tom’s presentation below. Play Previous Next